NEW YORK (GenomeWeb) – Trovagene today announced that it is establishing a European subsidiary, Trovagene Research Institute, charged with expanding the capabilities and adoption of the company's Precision Cancer Monitoring platform.
Alberto Bardelli, a University of Torino liquid biopsy researcher, will serve as scientific chair of TRI, Trovagene said. Bardelli has also been a member of the company's scientific advisory board for the past year.
Bardelli and colleagues recently published a study in Nature Medicine, showing that they were able to detect cancer mutations in blood that reflected clonal evolution and the development of resistance to anti-EGFR therapies in colorectal cancer patients.
Concurrent with the establishment of TRI, Trovagene said it has entered into a collaboration with the Department of Oncology at the University of Torino, which will focus specifically on advancing urine as a sample source for the detection and monitoring of cancer mutations.
"The University is looking forward to working with TRI to make Trovagene's novel liquid biopsy platform available to clinicians and patients in Europe," Giorgio Scagliotti, director of the Department of Oncology at the University of Torino, said in a statement.